Abstract: The present invention is directed to isolated nucleic acids containing functional polynucleotide sequences representing an enhancer element for the Gene Differentially Expressed in Prostate (GDEP). Such molecules are useful in conferring retinal specific transcriptional responsiveness on associated promoters and methods for directing retinal specific gene expression are accordingly disclosed.

Abstract: The invention provides a single nucleotide polymorphism (SNP) rs1042714 in the human ADRB2 gene (Gln27Glu) associated with a clinically meaningful reduction in intraocular pressure (IOP) in a human following treatment with a topical beta-blocker. Nucleic acids comprising the SNP are used to screen glaucoma-afflicted individuals to thereby provide an improved method for genotype-based prescribing of beta-blockers in glaucoma management.

Abstract: The present invention provides a method for use in treating a patient with an anticoagulant to optimize drug therapy and/or to prevent an adverse drug response. More particularly, the present invention relates to a method and system for use in treating a patient with Coumadin® or a substance containing warfarin. Methods of the present invention utilize variables that include the patient's CYP4F2 genotype.

Abstract: The invention provides a method for determining a genetic predisposition to prostate cancer in a male human subject. In one aspect, the method comprises determining whether the subject has the genotype GG of refSNP rs125555, where the genotype GG of refSNP rs125555 indicates that the subject is genetically predisposed to prostate cancer.

Abstract: The invention provides a single nucleotide polymorphism (SNP) rs1042714 in the human ADRB2 gene (Gln27Glu) associated with a clinically meaningful reduction in intraocular pressure (IOP) in a human following treatment with a topical beta-blocker. Nucleic acids comprising the SNP are used to screen glaucoma-afflicted individuals to thereby provide an improved method for genotype-based prescribing of beta-blockers in glaucoma management.

Abstract: The present invention provides a method of modulating TGF-? activity in a subject. Methods of the present invention comprise administering to the subject an effective amount of a compound of the formula: or a salt, prodrug, tautomer, hydrate, solvate, or stereoisomer thereof, wherein a is an integer from 0 to 4; each R1 is independently hydroxy, alkoxy, halide, alkyl, cyano, nitro, amino, monoalkylamino, dialkylamino, or carboxy; R2 is aryl, cycloalkyl, alkenyl, or alkyl, each of which is optionally substituted; each of X1 and X2 is independently O, S or NR3, wherein R3 is hydrogen or alkyl; X3 is hydrogen, alkoxy, alkyl, hydroxy, halide, amino, monoalkylamino, or dialkylamino; and X4 is alkoxy, hydroxy, halide, amino, monoalkylamino, or dialkylamino.

Abstract: The present invention is directed to isolated nucleic acids containing functional polynucleotide sequences representing an enhancer element for the Gene Differentially Expressed in Prostate (GDEP). Such molecules are useful in conferring retinal specific transcriptional responsiveness on associated promoters and methods for directing retinal specific gene expression are accordingly disclosed.

Abstract: The present invention provides a method for use in treating a patient with an anticoagulant to optimize drug therapy and/or to prevent an adverse drug response. More particularly, the present invention relates to a method and system for use in treating a patient with Coumadin® or a substance containing warfarin. Methods of the present invention utilize variables that include the patient's CYP4F2 genotype.